Non-antigen-specific and antigen-specific immune therapies for chronic hepatitis B: evidences from laboratory benches and patient's bedsides

Bibliography

• Iloeje UH, Yang HI, Chen CJ. Natural history of chronic hepatitis B: what exactly has REVEAL revealed? Liver Int 2012;32:1333-4
   PubMed Web of Science ®Google Scholar
• Chisari FV, Isogawa M, Wieland SF. Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris) 2010;58:258-66
   PubMed Web of Science ®Google Scholar
• Cassidy A, Mossman S, Olivieri A, et al. Hepatitis B vaccine effectiveness in the face of global HBV genotype diversity. Expert Rev Vaccin 2011;10:1709-15
   PubMed Web of Science ®Google Scholar
• Hilleman MR. Overview of the pathogenesis, prophylaxis, and therapeusis of viral hepatitis B, with focus on reduction to practical applications. Vaccine 2001;19:1837-48
   PubMed Web of Science ®Google Scholar
• Harkisoen S, Arends JE, van Erpecum KJ, et al. Hepatitis B viral load and risk of HBV-related liver disease: from East to West? Ann Hepatol 2012;11:164-71
   PubMed Web of Science ®Google Scholar
• Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-38
   PubMed Web of Science ®Google Scholar
• Wiegand J, van Bommel F, Berg T. Management of chronic hepatitis B; status and challenges beyond treatment guidelines. Semin Liver Dis 2010;30:361-7
   PubMed Web of Science ®Google Scholar
• Xu XW, Chen YG. Current therapy with nucleoside/nucleotide analogs for patients with chronic hepatitis B. Hepatobiliary Pancreat Dis Int 2006;5:350-9
   PubMedGoogle Scholar
• Lin CL, Kao JH. Recent advances in the treatment of chronic hepatitis B. Expert Opin Pharmacother 2011;12:2025-40
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ. Milestones and perspectives in viral hepatitis B. Liver Int 2011;31(Suppl 1):129-34
   PubMedGoogle Scholar
• Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001;34:593-602
   PubMed Web of Science ®Google Scholar
• Lin SM, Sheen IS, Chien RN, et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999;29:971-5
   PubMed Web of Science ®Google Scholar
• Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int 2009;29(Suppl 1):100-7
   PubMed Web of Science ®Google Scholar
• Wilt TJ, Shamliyan T, Shaukat A, et al. Management of chronic hepatitis B. Evid Rep Technol Assess (Full Rep) 2008;174:1-671
   PubMedGoogle Scholar
• Shamliyan TA, MacDonald R, Shaukat A, et al. Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference. Ann Int Med 2009;150:111-24
   PubMed Web of Science ®Google Scholar
• Zarski JP, Causse X, Cohard M, et al. A randomized, controlled trial of interferon alfa-2b alone and with simultaneous prednisone for the treatment of chronic hepatitis B. French Multicenter Group. J Hepatol 1994;20:735-41
   PubMed Web of Science ®Google Scholar
• Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31
   PubMed Web of Science ®Google Scholar
• Wang FS, Zhang Z. Host immunity influences disease progression and antiviral efficacy in humans infected with hepatitis B virus. Expert Rev Gastroenterol Hepatol 2009;3:499-512
   PubMedGoogle Scholar
• Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13:29-60
   PubMed Web of Science ®Google Scholar
• Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 2006;1:23-61
   PubMed Web of Science ®Google Scholar
• Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 2012;61:1754-64
   PubMed Web of Science ®Google Scholar
• Vierling JM. The immunology of hepatitis B. Clin Liver Dis 2007;11:727-59
   PubMedGoogle Scholar
• Boni C, Fisicaro P, Valdatta C, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007;81:4215-25
   PubMed Web of Science ®Google Scholar
• Boni C, Penna A, Bertoletti A, et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 2003;39:595-605
   PubMed Web of Science ®Google Scholar
• Boni C, Laccabue D, Lampertico P, et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 2012;143:963-73
   PubMed Web of Science ®Google Scholar
• Sprengers D, Janssen HL. Immunomodulatory therapy for chronic hepatitis B virus infection. Fund Clin Pharmacol 2005;19:17-26
   PubMed Web of Science ®Google Scholar
• Pol S, Michel ML. Therapeutic vaccination in chronic hepatitis B virus carriers. Expert Rev Vaccin 2006;5:707-16
   PubMed Web of Science ®Google Scholar
• Isogawa M, Robek MD, Furuichi Y, Chisari FV. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 2005;79:7269-72
   PubMed Web of Science ®Google Scholar
• Schultz U, Chisari FV. Recombinant duck interferon gamma inhibits Duck hepatitis B virus replication in primary hepatocytes. J Virol 1999;73:3162-8
   PubMed Web of Science ®Google Scholar
• Kimura K, Kakimi K, Wieland S, et al. Activated intrahepatic antigen-presenting cells inhibit hepatitis B virus replication in the liver of transgenic mice. J Immunol 2002;169:5188-95
   PubMed Web of Science ®Google Scholar
• Thermet A, Buronfosse T, Werle-Lapostolle B, et al. DNA vaccination in combination or not with lamivudine treatment breaks humoral immune tolerance and enhances cccDNA clearance in the duck model of chronic hepatitis B virus infection. J Gen Virol 2008;89:1192-201
   PubMed Web of Science ®Google Scholar
• Lu M, Yao X, Xu Y, et al. Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model. J Virol 2008;82:2598-603
   PubMed Web of Science ®Google Scholar
• D'Ugo E, Canitano A, Catone S, et al. Effect of an immunogenic complex containing WHV viral particles and non-neutralizing anti-HBs antibodies on the outcome of WHV infection in woodchucks. J Med Virol 2011;83:178-86
   PubMed Web of Science ®Google Scholar
• Shata MT, Pfahler W, Brotman B, et al. Attempted therapeutic immunization in a chimpanzee chronic HBV carrier with a high viral load. J Med Primatol 2006;35:165-7
   PubMed Web of Science ®Google Scholar
• Akbar SM, Kajino K, Tanimoto K, et al. Placebo-controlled trial of vaccination with hepatitis B virus surface antigen in hepatitis B virus transgenic mice. J Hepatol 1997;26:131-7
   PubMed Web of Science ®Google Scholar
• Morrey JD, Motter NE, Chang S, Fairman J. Breaking B and T cell tolerance using cationic lipid--DNA complexes (CLDC) as a vaccine adjuvant with hepatitis B virus (HBV) surface antigen in transgenic mice expressing HBV. Antivir Res 2011;90:227-30
   PubMed Web of Science ®Google Scholar
• Tilg H, Vogel W, Tratkiewicz J, et al. Pilot study of natural human interleukin-2 in patients with chronic hepatitis B. Immunomodulatory and antiviral effects. J Hepatol 1993;19:259-67
   PubMed Web of Science ®Google Scholar
• Artillo S, Pastore G, Alberti A, et al. Double-blind, randomized controlled trial of interleukin-2 treatment of chronic hepatitis B. J Med Virol 1998;54:167-72
   PubMed Web of Science ®Google Scholar
• Carreno V, Zeuzem S, Hopf U, et al. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B. J Hepatol 2000;32:317-24
   PubMed Web of Science ®Google Scholar
• Martin J, Quiroga JA, Bosch O, Carreno V. Changes in cytokine production during therapy with granulocyte-macrophage colony-stimulating factor in patients with chronic hepatitis B. Hepatology 1994;20:1156-61
   PubMed Web of Science ®Google Scholar
• Ruiz-Moreno M, Garcia R, Rua MJ, et al. Levamisole and interferon in children with chronic hepatitis B. Hepatology 1993;18:264-9
   PubMed Web of Science ®Google Scholar
• Farhat BA, Marinos G, Daniels HM, et al. Evaluation of efficacy and safety of thymus humoral factor-gamma 2 in the management of chronic hepatitis B. J Hepatol 1995;23:21-7
   PubMed Web of Science ®Google Scholar
• Woltman AM, Ter Borg MJ, Binda RS, et al. Alpha-galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled Phase I/II trial. Antivir Ther 2009;14:809-18
   PubMed Web of Science ®Google Scholar
• Hirayama C, Suzuki H, Ito M, et al. Propagermanium: a nonspecific immune modulator for chronic hepatitis B. J Gastroenterol 2003;38:525-32
   PubMed Web of Science ®Google Scholar
• Israeli E, Safadi R, Melhem A, et al. Induction of oral immune regulation towards liver-extracted proteins for treatment of chronic HBV and HCV hepatitis: results of a phase I clinical trial. Liver Int 2004;24:295-307
   PubMed Web of Science ®Google Scholar
• Iino S, Toyota J, Kumada H, et al. The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial. J Viral Hepat 2005;12:300-6
   PubMed Web of Science ®Google Scholar
• Yang YF, Zhao W, Zhong YD, et al. Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis. Antiviral Res 2008;77136-41
   Google Scholar
• Lampertico P, Vigano M, Colombo M. Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon? Liver Int 2013;33(Suppl 1):157-63
   PubMedGoogle Scholar
• Fisicaro P, Valdatta C, Massari M, et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 2010;138:682-93
   PubMed Web of Science ®Google Scholar
• Maini MK, Boni C, Lee CK, et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 2000;191:1269-80
   PubMed Web of Science ®Google Scholar
• Pol S, Driss F, Michel ML, et al. Specific vaccine therapy in chronic hepatitis B infection. Lancet 1994;344(8918):342
   PubMed Web of Science ®Google Scholar
• Senturk H, Tabak F, Akdogan M, et al. Therapeutic vaccination in chronic hepatitis B. J Gastroenterol Hepatol 2002;17:72-6
   PubMed Web of Science ®Google Scholar
• Wang XY, Zhang XX, Yao X, et al. Serum HBeAg sero-conversion correlated with decrease of HBsAg and HBV DNA in chronic hepatitis B patients treated with a therapeutic vaccine. Vaccine 2010;28:8169-74
   PubMed Web of Science ®Google Scholar
• Wen YM, Wu XH, Hu DC, et al. Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy. Lancet 1995;345:1575-6
   PubMed Web of Science ®Google Scholar
• Xu DZ, Zhao K, Guo LM, et al. A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS One 2008;3:e2565
   PubMed Web of Science ®Google Scholar
• Dahmen A, Herzog-Hauff S, Bocher WO, et al. Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B. J Med Virol 2002;66:452-60
   PubMed Web of Science ®Google Scholar
• Horiike N, Fazle Akbar SM, Michitaka K, et al. In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. J Clin Virol 2005;32:156-61
   PubMed Web of Science ®Google Scholar
• Helvaci M, Kizilgunesler A, Kasirga E, et al. Efficacy of hepatitis B vaccination and interferon-alpha-2b combination therapy versus interferon-alpha-2b monotherapy in children with chronic hepatitis B. J Gastroenterol Hepatol 2004;19:785-91
   PubMed Web of Science ®Google Scholar
• Hoa PT, Huy NT, Thu le T, et al. Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B. Antimicrob Agents Chemother 2009;53:5134-40
   PubMed Web of Science ®Google Scholar
• Wright TL, Tong MJ, Hsu HH. Phase 1 study of a potent adjuvanted hepatitis B vaccine (HBV/MF59) for therapy of chronic hepatitis. Hepatology 1999;30:421A
   Web of Science ®Google Scholar
• Yang FQ, Yu YY, Wang GQ, et al. A pilot randomized controlled trial of dual-plasmid HBV DNA vaccine mediated by in vivo electroporation in chronic hepatitis B patients under lamivudine chemotherapy. J Viral Hepat 2012;19:581-93
   PubMed Web of Science ®Google Scholar
• Chen M, Li YG, Zhang DZ, et al. Therapeutic effect of autologous dendritic cell vaccine on patients with chronic hepatitis B: a clinical study. World J Gastroenterol 2005;11:1806-8
   PubMed Web of Science ®Google Scholar
• Akbar SM, Furukawa S, Horiike N, et al. Safety and immunogenicity of hepatitis B surface antigen-pulsed dendritic cells in patients with chronic hepatitis B. J Viral Hepat 2011;18:408-14
   PubMed Web of Science ®Google Scholar
• Luo J, Li J, Chen RL, et al. Autologus dendritic cell vaccine for chronic hepatitis B carriers: a pilot, open label, clinical trial in human volunteers. Vaccine 2010;28:2497-504
   PubMed Web of Science ®Google Scholar
• Michel ML, Mancini-Bourgine M. Therapeutic vaccination against chronic hepatitis B virus infection. J Clin Virol 2005;34(Suppl 1):S108-14
   PubMed Web of Science ®Google Scholar
• Dikici B, Bosnak M, Ucmak H, et al. Failure of therapeutic vaccination using hepatitis B surface antigen vaccine in the immunotolerant phase of children with chronic hepatitis B infection. J Gastroenterol Hepatol 2003;18:218-22
   PubMed Web of Science ®Google Scholar
• Pol S, Nalpas B, Driss F, et al. Multicenter study group. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol 2001;34:917-21
   PubMed Web of Science ®Google Scholar
• Vandepapeliere P, Lau GK, Leroux-Roels G, et al. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 2007;25:8585-97
   PubMed Web of Science ®Google Scholar
• Webster GJ, Reignat S, Brown D, et al. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 2004;78:5707-19
   PubMed Web of Science ®Google Scholar
• Maini MK, Boni C, Ogg GS, et al. Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology 1999;117:1386-96
   PubMed Web of Science ®Google Scholar
• Penna A, Del Prete G, Cavalli A, et al. Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B. Hepatology 1997;25:1022-7
   PubMed Web of Science ®Google Scholar
• Heathcote J, McHutchison J, Lee S, et al. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Hepatology 1999;30:531-6
   PubMed Web of Science ®Google Scholar
• Livingston BD, Alexander J, Crimi C, et al. Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans. J Immunol 1999;162:3088-95
   PubMed Web of Science ®Google Scholar
• Akbar SM, Chen S, Al-Mahtab M, et al. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus. Antivir Res 2012;96:59-64
   PubMed Web of Science ®Google Scholar
• Akbar SM, Yoshida O, Chen S, et al. Immune modulator and antiviral potential of dendritic cells pulsed with both hepatitis B surface antigen and core antigen for treating chronic HBV infection. Antivir Ther 2010;15:887-95
   PubMed Web of Science ®Google Scholar
• Akbar SM, Al-Mahtab M, Rahman S, et al. Therapeutic potential of a novel therapeutic vaccine containing both hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg) administered through mucosal and parental route in patients with chronic hepatitis B. Hepatology 2010;52(Suppl):438A-9A
   Google Scholar
• Muller C, Knoflach P, Zielinski CC. Reduced production of immunoreactive interleukin-1 by peripheral blood monocytes of patients with acute and chronic viral hepatitis. Dig Dis Sci 1993;38:477-81
   PubMed Web of Science ®Google Scholar
• Rossol S, Marinos G, Carucci P, et al. Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B. J Clin Invest 1997;99:3025-33
   PubMed Web of Science ®Google Scholar
• Schlaak JF, Tully G, Lohr HF, et al. HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro- and anti-inflammatory cytokines. Clin Exp Immunol 1999;115:508-14
   PubMed Web of Science ®Google Scholar
• Maini MK, Schurich A. The molecular basis of the failed immune responses in chronic HBV: therapeutic implications. J Hepatol 2010;52:616-19
   PubMed Web of Science ®Google Scholar
• Akbar SM, Abe M, Masumoto T, et al. Mechanism of action of vaccine therapy in murine hepatitis B virus- carriers: vaccine-induced activation of antigen presenting dendritic cells. J Hepatol 1999;30:755-64
   PubMed Web of Science ®Google Scholar
• Jung MC, Gruner N, Zachoval R, et al. Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers. Vaccine 2002;20:3598-612
   PubMed Web of Science ®Google Scholar
• Couillin I, Pol S, Mancini M, et al. Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J Infect Dis 1999;180:15-26
   PubMed Web of Science ®Google Scholar
• Koziel MJ. What once was lost, now is found: restoration of hepatitis B-specific immunity after treatment of chronic hepatitis B. Hepatology 1999;29:1331-3
   PubMed Web of Science ®Google Scholar
• Jiang X, Zhang M, Lai Q, et al. Restored circulating invariant NKT cells are associated with viral control in patients with chronic hepatitis B. PLoS One 2011;6:e28871
   PubMedGoogle Scholar
• Tang L, Yang J, Liu W, et al. Liver sinusoidal endothelial cell lectin, LSECtin, negatively regulates hepatic T-cell immune response. Gastroenterology 2009;137:1498-508
   PubMed Web of Science ®Google Scholar
• Chen S, Akbar SM, Abe M, et al. Immunosuppressive functions of hepatic myeloid-derived suppressor cells of normal mice and in a murine model of chronic hepatitis B virus. Clin Exp Immunol 2011;166:134-42
   PubMed Web of Science ®Google Scholar
• Micco L, Peppa D, Loggi E, et al. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J Hepatol 2013;58:225-33
   PubMed Web of Science ®Google Scholar
• Akbar SM, Hiasa Y, Mishiro S, et al. Treatment of hepatitis B virus-infected patients: utility of therapeutic recommendations in developing countries. Expert Opin Pharmacother 2009;10:1605-14
   PubMed Web of Science ®Google Scholar
• Wiersma ST, McMahon B, Pawlotsky JM, et al. Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. Liver Int 2011;31:755-61
   PubMedGoogle Scholar
• Akbar SM, Al-Mahtab M, Hiasa Y. Future aspects of therapy for hepatitis B virus infection: value of surrogate markers, innovative therapy, and global collaboration. J Gastroenterol 2011;46:717-23
   PubMed Web of Science ®Google Scholar
• Bohne F, Chmielewski M, Ebert G, et al. T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes. Gastroenterology 2008;134:239-47
   PubMed Web of Science ®Google Scholar
• Gehring AJ, Xue SA, Ho ZZ, et al. Engineering virus-specific T cells that target HBV-infected hepatocytes and hepatocellular carcinoma cell lines. J Hepatol 2011;55:103-10
   PubMed Web of Science ®Google Scholar